Skip to main content
×
Home

Evidence and values: paying for end-of-life drugs in the British NHS

  • Kalipso Chalkidou (a1)
Abstract
Abstract

In January 2009, Britain's National Institute for Health and Clinical Excellence (NICE), following a very public debate triggered by its decision, six months earlier, provisionally to rule against the adoption by the National Health Service (NHS) of an expensive drug for advanced renal cancer, introduced a new policy for evaluating pharmaceuticals for patients nearing the end of their lives. NICE's so-called end-of-life (EOL) guidance for its Committees effectively advises them to deviate from the Institute's threshold range and to value the lives of (mostly) dying cancer patients more than the lives of those suffering from other, potentially curable, chronic or acute conditions. This article tells the story of the EOL guidance. Through looking at specific EOL decisions between 2009 and 2011 and the reactions by stakeholders to these decisions and the policy itself, it discusses the triggers for NICE's EOL guidance, the challenges NICE faces in implementing it and the policy's putative implications for the future role of NICE in the NHS, especially in the context of value-based reforms in the pricing and evaluation of pharmaceuticals, currently under consideration.

Copyright
Corresponding author
*Correspondence to: Kalipso Chalkidou, NICE, 71 High Holborn, London WC1V 6NA, UK. Email: Kalipso.Chalkidou@nice.org.uk
References
Hide All
Boseley S. (2010), ‘Government's drug rationing body, Nice, to lose powers to decide on new drugs’, The Guardian.
Chalkidou K., Culyer A. J., Littlejohns P., Doyle N.Hoy A. (2008), ‘Imbalances in funding for clinical and public health research in the UK: can NICE research recommendations make a difference?’, Evidence & Policy, 4(3): 357371.
Clement F. M., Harris A., Li J. J., Yong K., Lee K. M.Manns B. J. (2009), ‘Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada’, Journal of the American Medical Association, 302(13): 14371443.
Department of Health. (2008), ‘The 2009 Pharmaceutical Price Regulation Scheme’.
Department of Health. (2010), ‘Equity and excellence: Liberating the NHS’. London: Crown.
Department of Health. (2011), ‘The Cancer Drugs Fund. Government response to consultation’.
Department of Health. (2011), ‘A new value-based approach to the pricing of branded medicines - a consultation’.
Editorial (2010), ‘New £50 million cancer fund already intellectually bankrupt’, The Lancet, 376(9739): 389.
Faden R. R.Chalkidou K. (2011), ‘Determining the value of drugs – the evolving British experience’, New England Journal of Medicine, 364(14): 12891291.
Faden R. R., Chalkidou K., Appleby J., Waters H. R.Leider J. P. (2009), ‘Expensive cancer drugs: a comparison between the United States and the United Kingdom’, Milbank Q, 87(4): 789819.
Fojo T.Grady C. (2009), ‘How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question’, J Natl Cancer Inst, 101: 10441048.
Harris G. (2008), ‘British Balance Benefit vs. Cost of Latest Drugs’, The New York Times.
Health Select Committee (2009), ‘Top-up fees Fourth Report of Session 2008–09’, in House of Commons (ed.), London: Stationary Office.
Jack A. (2011), ‘GPs welcome rethink on NICE's role in NHS’, Financial Times.
Judd T. (2011), ‘Doctors call for end to NHS postcode “injustice” ’, The Independent.
Lawrance J. (2008), ‘Ministers in U-turn over the right to ‘top-up’ NHS treatments’, The Independent.
Littlejohns P.Kelly M. (2005), ‘The changing face of NICE: the same but different’, The Lancet, 366(9488): 791794.
MacDonald V. (2011), ‘NHS: Government U-turn gives drug powers back to NICE’, Channel 4 News.
Meropol N. J., Schrag D., Smith T. J., Mulvey T. M., Langdon R. M. Jr, Blum D., Ubel P. A., Schnipper L. E. (2009), ‘American Society of Clinical Oncology guidance statement: the cost of cancer care’, J Clin Oncol, 27: 38683874.
Moore A. (2008), ‘All or nothing: patients are told no to private top-ups’, Health Services Journal.
National Confidential Enquiry into Patient Outcome and Death (2008), ‘For better, for worse? A review of the care of patients who died within 30 days of receiving systemic anti-cancer therapy’.
Pearson S. D.Rawlins M. D. (2005), ‘Quality, innovation, and value for money: NICE and the British National Health Service’, Journal of the American Medical Association, 294(20): 26182622.
Raftery J. (2009), ‘End of life drugs – what premium? Pt 1 & 2’, BMJ Group Blogs. http://www.bmj.com/content/340/bmj.c1672.full
Raftery J. (2010), ‘Multiple sclerosis risk sharing scheme: a costly failure’, British Medical Journal, 340: c1672.
Ramesh R. (2010), ‘Emergency fund to pay for ‘too expensive’ cancer drugs’, The Guardian.
Rawlins M., Barnett D.Stevens A. (2010), ‘Pharmacoeconomics: NICE's approach to decision-making’, British Journal of Clinical Pharmacology, 70(3): 346349.
Rawlins M. D. (2005), ‘Pharmacopolitics and deliberative democracy’, Clinical Medicine, 5(5): 471475.
Rawlins M. D.Culyer A. J. (2004), ‘National Institute for Clinical Excellence and its value judgments’, British Medical Journal, 329(7459): 224227.
Richards M. (2008), ‘Improving access to medicines for NHS patients’.
Robins J. (2008), ‘Patients who pay for cancer care still face NHS costs’, The Observer.
Rose D. (2008), ‘NHS to widen access to expensive drugs for the dying’, The Times.
Shah K. K., Cookson R., Culyer A. J.Littlejohns P. (2011), ‘NICE's social value judgements about equity in health and health care’, CHE Discussion Papers, 70.
Steinbrook R. (2008), ‘Saying no isn't NICE – the travails of Britain's National Institute for Health and Clinical Excellence’, New England Journal of Medicine, 359(19): 19771981.
Williamson S. (2010), ‘Patient access schemes for high-cost cancer medicines’, Lancet Oncology, 11(2): 111112.
Winnett R. (2008), ‘NHS patients will be allowed to pay for private ‘top up’ care, says Alan Johnson’, The Daily Telegraph.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Health Economics, Policy and Law
  • ISSN: 1744-1331
  • EISSN: 1744-134X
  • URL: /core/journals/health-economics-policy-and-law
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 3
Total number of PDF views: 45 *
Loading metrics...

Abstract views

Total abstract views: 237 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 20th November 2017. This data will be updated every 24 hours.